Petros Grivas, MD, PhD

Physician
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Clinical Director, Genitourinary Cancers Program
UW Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Specialty:
Medical Oncology
“At SCCA, I belong to a family of innovative, patient-centered providers.”
— Dr. Grivas
What drew you to oncology?

Ever since I was young, I’ve wanted to help other people. I knew a family friend who was a physician, and he served as a great example of how I could channel this desire, combining knowledge and compassion so that I could be of service to a community. I chose to focus on genitourinary cancers because they’re a set of very common diseases affecting the urinary tract and male reproductive system, so I felt pursuing this specialty would allow me to make a difference in the lives of many. I see this area of oncology as an opportunity to bring together my interest in innovative research and patient care.

How do you like to work with patients?

I am dedicated to providing outstanding cancer care, which to me means taking a personalized approach with each patient and being efficient with time and resources. I hope to learn what brought you in and what your goals and expectations are — both for each visit and in the long term. While I bring a wealth of knowledge about genitourinary cancers and the latest research developments, I also believe that the little things, like a warm smile and a conversation held eye-to-eye, matter a great deal.

Provider background

Specialty: Medical Oncology

Genitourinary cancers

I am a board-certified medical oncologist who specializes in treating patients with genitourinary cancers, such as bladder cancer and prostate cancer. My background includes leading the bladder/urothelial cancer program at the Cleveland Clinic and caring for patients at the University of Michigan, Ann Arbor. Currently, I serve as the director of UW Medicine's Genitourinary Cancers Program, giving frequent lectures, educating other oncologists and trainees and publishing novel research. I also conduct clinical trials, one of which led to the FDA approval of new drugs for bladder and urothelial cancer.

Diseases treated

Education, experience and certifications
Medical Degree
University of Patras School of Medicine, Greece
Residency
Drexel University College of Medicine/Hahnemann University Hospital, Internal Medicine
Fellowship
University of Michigan, Hematology-Oncology
Board Certification
Medical Oncology, 2013, American Board of Internal Medicine; Internal Medicine, 2010, American Board of Internal Medicine
Other
PhD, University of Patras School of Medicine, Greece
Languages
English
Italian
Greek

Stories

New data on risks and treatment for patients with cancer and COVID
New data on risks and treatment for patients with cancer and COVID

Since the COVID-19 pandemic began, oncologists have grappled with questions about potential risks and treatment changes for their cancer patients. To address these and many other questions, Seattle Cancer Care Alliance (SCCA) partnered with Fred Hutch, Vanderbilt University and other organizations to form the COVID-19 Cancer Consortium (CCC19).

Research

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Complete title
PATRIOT-II: AmbisPective ObservATional Multi-centeR Study for FIrst Line Maintenance Of Avelumab in UroThelIal CarcInoma
Study ID:
NCT03606174
Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma
Complete title
A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma
Study ID:
Complete title
Characterization of the Peripheral Blood Signatures in Patients Treated with PD1/PDL-1 Checkpoint Inhibitors

Publications

Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Press

SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

Dr. Grivas on Attempts to Improve Upon Chemotherapy in Urothelial Cancer

SCCA’s Petros Grivas, MD, spoke with OncLive about attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

Overview of Advanced Urothelial Carcinoma

SCCA’s Dr. Petros Grivas moderated a webinar discussion sponsored by Cancer Network that addressed patient presentation and the major risk factors for urothelial cancer.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.

Insurance

SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers